Zacks Investment Research | Jan 21, 2022 12:06AM ET
Sanofi (NASDAQ:SNY) industry ’s rally of 17.5%.
Regeneron’s stock has risen 14% in the past year against the industry ’s decrease of 37%
Dupixent is being jointly marketed by Regeneron and Sanofi under a global collaboration agreement. Sanofi records global net product sales of Dupixent while Regeneron records its share of profits/losses in connection with global sales of the drug.
Dupixent is now approved in the United States, the EU and some other countries for three type II inflammatory diseases, namely uncontrolled chronic rhinosinusitis with nasal polyposis, moderate-to-severe asthma and moderate-to-severe atopic dermatitis. The frequent label expansion approvals are driving the drug’s sales higher.
Dupixent has become the key driver of the top line for Sanofi and profits for Regeneron. Dupixent generated third-quarter global product sales of $1.66 billion, which were recorded by Sanofi. Sanofi and Regeneron are also studying dupilumab in late-stage studies in a broad range of diseases driven by type 2 inflammation like chronic obstructive pulmonary disease, eosinophilic esophagitis, bullous pemphigoid, chronic spontaneous urticaria and some more.
With outside U.S. revenues accelerating and multiple approvals for new indications expected in the near future, Dupixent’s sales are expected to be higher.
Sanofi currently has a Zacks Rank #5 (Strong Sell). Regeneron presently carries a Zacks Rank #2 (Buy).
You can see BNTX , which have a Zacks Rank of 1 (Strong Buy),
Pfizer’s stock has risen 52.3% in the past year. Estimates for Pfizer’s 2022 earnings have gone up from $3.86 to $5.80 over the past 60 days.
Pfizer’s earnings performance has been mixed, with the company exceeding earnings expectations in three of the last four quarters while missing in one. PFE has a four-quarter earnings surprise of 10.85%, on average.
BioNTech’s stock has surged 64% in the past year. Estimates for BioNTech’s 2022 earnings have gone up from $31.14 to $32.52 over the past 60 days.
BioNTech topped earnings estimates in each of the last four quarters. BioNTech has a four-quarter earnings surprise of 132.44%, on average.
(We are reissuing this article to correct a mistake. The original article, issued on January 20, 2022, should no longer be relied upon.)
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer (NYSE:SAM) Company which shot up +143.0% in little more than 9 months and NVIDIA (NASDAQ:NVDA) which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.